Just Published: "China Lamivudine Market, 2010-2019"

Acoording to the report issued by the Joint United Nations Programme on HIV and AIDS in 2014, by the end of 2013, patients with human immune deficiency virus/acquired immune deficiency syndrome (HIV/ AIDS) had amounted to 35 million and the number of new cases of HIV/AIDS had been 6000 a day on average. And by the end of 2011, patients with HIV/ AIDS in China was estimated to be 0.78 million, the number of new cases of HIV/AIDS was 48,000 and people die of diseases related with AIDS reached 28,000.
Lamivudine, an important drug for hepatitis B Virus (HBV) and AIDS, is one of the products regulated by the Chinese government to be provided to patients with AIDS (patients with hepatitis B not included) for free. As an antiviral nucleotide analog, lamivudine can competitively inhibit the synthesis and elongation of viral DNA chain. First used by some countries in Europe and North America for the treatment of AIDS in the early 1990s, lamivudine was approved by FDA to be used for the treatment of hepatitis B in 1998 after some medical experts discovered its inhibiting effect on HBV DNA in the middle 1990s. Lamivudine was approved by CFDA mainly as hepatitis B drug and began its sales in China in 1999.
Lamivudine develops fast after entering China with sales value reaching up to CNY 307 million in 2012 despite its gradual drop since 2013. GlaxoSmithKline Pharmaceuticals (Suzhou) Limited, Beijing Wansheng Pharmaceutical Co., Ltd, Burroughs Wellcome & Company (UK) and Fujian Cosunter Pharmaceutical Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline Pharmaceuticals (Suzhou) Limited had the largest market share of about 72% for sales value in 2014.
With the large amounts of patients with hepatitis B and AIDS in China, the market size of lamivudine is expected to have growth potential.

Full Report Details at
- http://www.fastmr.com/prod/1020587_china_lamivudine_20102019.aspx?afid=301

Readers can get at least the following information from this report:

* market size of lamivudine in China
* competitive landscape of lamivudine in Chinese market
* price of lamivudine made by different enterprises in China
* market outlook of lamivudine in China

The author suggests the following groups of people purchase this report:

* manufacturers of anti-HBV drugs
* manufacturers of anti-AIDS drugs
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned in this Report: Anhui Biochem United Pharmaceutical Co., Ltd, Fujian Cosunter Pharmaceutical Co., Ltd, Beijing Wansheng Pharmaceutical Co., Ltd, GlaxoSmithKline Pharmaceuticals (Suzhou) Limited, Hunan Qianjin Xiangjiang Pharmaceutical Industry Co., Ltd

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Tobira Therapeutics, Inc. - Product Pipeline Review - 2014
- HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth
- Lupin Limited (LUPIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- China Adefovir Market, 2010-2019